Skip to main content
. Author manuscript; available in PMC: 2020 May 13.
Published in final edited form as: Obesity (Silver Spring). 2016 Mar 29;24(6):1244–1256. doi: 10.1002/oby.21463

Figure 5.

Figure 5

SB203580 prevented renal disorders and hypertrophy induced by obesity. After treatment with SB203580, mice kidney morphology changes induced by obesity were prevented. (A) Spot urine samples were collected to measure and calculate the UACR of SB203580 treated mice. (B) Ratio of kidney weight and tibia length was calculated. (C) PAS staining was performed to evaluate the general morphology changes of glomerular and tubular area. IHC staining of PCNA was assayed to detect the glomeruli cell proliferation. Tubular IF of IL-6 staining revealed the inflammation level of kidney. (D) Semiquantitative analysis of glomerular PAS positive staining area, tubular vacuolization levels, glomerular area, PCNA positive cells, and IF positive area (400×, scale bar 100 μm). Data are presented as the mean ± S.D. after normalizing to ND/N.Zn (n = 5). *, P < 0.05 vs. corresponding ND/N.Zn; #, P < 0.05 vs. corresponding HFD/N.Zn; &, P < 0.05 vs. corresponding HFD/L.Zn.